Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

The Washington University trial comes as part of a larger platform study which hopes to understand if Alzheimer's disease can ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

We recently published a list of Jim Cramer’s Thoughts on These 7 Stocks. In this article, we are going to take a look at ...

Children who inherit genetic mutations from parents with early-onset Alzheimer’s typically show signs of dementia at the same ...

Novo Nordisk CEO Lars Fruergaard Jørgensen weighs in the company's latest obesity drug offering, including its new oral weight loss candidate.

With a market cap of $799.5 billion, Indianapolis, Indiana-based Eli Lilly and Company (LLY) is a leading global ...

We recently compiled a list of the 12 Safest Stocks to Buy According to Hedge Funds. In this article, we are going to take a ...

Eli Lilly's long, successful history of dominating the diabetes market is more important than any specific drug or pipeline program. This doesn't happen by accident. The company has created and ...

Now that the year is underway and a new presidential administration is in place in Washington, let’s consider the environment ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE ... have a complex performance history. Since their inception in 1949, hedge funds have evolved significantly ...

Weight-loss drugs are transforming health care and Wall Street, but exciting prospects don’t necessarily mean a company is a good investment.